Efficacy of mesna in preventing further cyclophosphamide-induced hemorrhagic cystitis.
Mesna is a sulfhydryl compound that reacts with the metabolites of cyclophosphamide that are excreted in the urine and may produce bladder wall irritation. Mesna is converted in the blood to a biochemically inactive compound that is reduced back to mesna in the kidneys. In this way it has the potential to protect the bladder mucosa without interfering with the antineoplastic effect of cyclophosphamide. Twenty-two patients who had developed hemorrhagic cystitis from cyclophosphamide were treated again with cyclophosphamide and mesna prophylaxis. A total of 68 cycles of cyclophosphamide were given with mesna, with a median of three cycles per patient. A recurrence of cystitis was prevented in all but one patient. Thus, mesna is effective in preventing recurrent cystitis in patients receiving further cyclophosphamide.
D000293:Adolescent; D000328:Adult; D002648:Child; D003520:Cyclophosphamide / Q000009:adverse effects*; D003556:Cystitis / Q000139:chemically induced* / Q000517:prevention & control; D003558:Cystoscopy; D005260:Female; D006417:Hematuria / Q000139:chemically induced* / Q000517:prevention & control; D006801:Humans; D008297:Male; D008623:Mercaptoethanol / Q000031:analogs & derivatives*; D015080:Mesna / Q000627:therapeutic use*; D011446:Prospective Studies; D012208:Rhabdomyosarcoma / Q000188:drug therapy; D012509:Sarcoma / Q000188:drug therapy
D008623:Mercaptoethanol; D003520:Cyclophosphamide; D015080:Mesna